TY - JOUR
T1 - Malignancy-Associated Membranous Nephropathy with Positive Anti-PLA2R Autoantibodies
T2 - Coincidence or Connection
AU - Baker, Lyle W.
AU - Jimenez-Lopez, Jaime
AU - Geiger, Xochiquetzal J.
AU - Aslam, Nabeel
N1 - Publisher Copyright:
© 2021
PY - 2021/11/18
Y1 - 2021/11/18
N2 - Membranous nephropathy (MN) is currently classified as either primary - often associated with positive anti-phospholipase-A2 receptor (PLA2R) autoantibodies - or as secondary - associated with malignancy, infection, medications, or autoimmune disease. We present a case of biopsy-proven MN with very high serum titer of anti-PLA2R autoantibodies in a patient with a synchronous diagnosis of poorly differentiated esophageal adenocarcinoma and renal cell carcinoma who presented with nephrotic syndrome. Based on the current classification, MN in the presence of active malignancy is diagnosed as secondary and unlikely to have positive anti-PLA2R autoantibodies. This raises several questions: whether this patient has secondary MN associated with malignancy and coincidentally discovered anti-PLA2R autoantibodies, primary MN due to anti-PLA2R autoantibodies with coincidentally discovered malignancy, or whether malignancy can induce the formation of anti-PLA2R autoantibodies that result in MN. This case report highlights the importance of age-appropriate cancer screening, even in patients with presumed primary MN and positive anti-PLA2R autoantibodies.
AB - Membranous nephropathy (MN) is currently classified as either primary - often associated with positive anti-phospholipase-A2 receptor (PLA2R) autoantibodies - or as secondary - associated with malignancy, infection, medications, or autoimmune disease. We present a case of biopsy-proven MN with very high serum titer of anti-PLA2R autoantibodies in a patient with a synchronous diagnosis of poorly differentiated esophageal adenocarcinoma and renal cell carcinoma who presented with nephrotic syndrome. Based on the current classification, MN in the presence of active malignancy is diagnosed as secondary and unlikely to have positive anti-PLA2R autoantibodies. This raises several questions: whether this patient has secondary MN associated with malignancy and coincidentally discovered anti-PLA2R autoantibodies, primary MN due to anti-PLA2R autoantibodies with coincidentally discovered malignancy, or whether malignancy can induce the formation of anti-PLA2R autoantibodies that result in MN. This case report highlights the importance of age-appropriate cancer screening, even in patients with presumed primary MN and positive anti-PLA2R autoantibodies.
KW - Anti-phospholipase-A2 receptor antibodies
KW - Malignancy
KW - Membranous glomerulonephritis
KW - Nephrotic syndrome
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85120339602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120339602&partnerID=8YFLogxK
U2 - 10.1159/000520399
DO - 10.1159/000520399
M3 - Article
AN - SCOPUS:85120339602
SN - 2296-9705
VL - 11
SP - 334
EP - 339
JO - Case Reports in Nephrology and Dialysis
JF - Case Reports in Nephrology and Dialysis
IS - 3
ER -